Thomas Lewis Adams
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Thomas Lewis Adams has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- Christian Tiede
School of Molecular and Cellular Biology, University of Leeds, Leeds, United Kingdom
4 shared publications - Darren Charles Tomlinson
School of Molecular and Cellular Biology, University of Leeds, Leeds, United Kingdom
3 shared publications - Anna Ah-San Tang
University of Leeds
2 shared publications Darren C. Tomlinson
The Astbury Centre for Structural Molecular Biology, University of Leeds, Leeds, United Kingdom
2 shared publicationsMichael J. McPherson
School of Molecular and Cellular Biology, Astbury Centre for Structural and Molecular Biology, University of Leeds, Leeds, UK
2 shared publications- Ajinkya Rao
School of Molecular and Cellular Biology, Astbury Centre for Structural and Molecular Biology, University of Leeds, Leeds, UK
1 shared publication
Latest Publications
- Open Access
- 25 July 2024
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (15) , 3917-3928
Affimer reagents as tool molecules to modulate platelet GPVI-ligand interactions and specifically bind GPVI dimer
Glycoprotein VI (GPVI) plays a key role in collagen-induced platelet aggregation. Affimers are engineered binding protein alternatives to antibodies. We screened and characterized GPVI-binding Affimers as novel tools to probe GPVI function. Among the positive clones, M17, D22, and D18 bound GPVI with the highest affinities (dissociation constant (KD) in the nanomolar range). These Affimers inhibited GPVI-collagen-related peptide (CRP)-XL/collagen interactions, CRP-XL/collagen-induced platelet aggregation, and D22 also inhibited in vitro thrombus formation on a collagen surface under flow. D18 bound GPVI dimer but not monomer. GPVI binding was increased for D18 but not M17/D22 upon platelet activation by CRP-XL and adenosine 5′-diphosphate. D22 but not M17/D18 displaced nanobody 2 (Nb2) binding to GPVI, indicating similar epitopes for D22 with Nb2 but not for M17/D18. Mapping of binding sites revealed that D22 binds a site that overlaps with Nb2 on the D1 domain, whereas M17 targets a site on the D2 domain, overlapping in part with the glenzocimab binding site, a humanized GPVI antibody fragment antigen-binding fragment. D18 targets a new region on the D2 domain. We found that D18 is a stable noncovalent dimer and forms a stable complex with dimeric GPVI with 1:1 stoichiometry. Taken together, our data demonstrate that Affimers modulate GPVI-ligand interactions and bind different sites on GPVI D1/D2 domains. D18 is dimer-specific and could be used as a tool to detect GPVI dimerization or clustering in platelets. A dimeric epitope regulating ligand binding was identified on the GPVI D2 domain, which could be used for the development of novel bivalent antithrombotic agents selectively targeting GPVI dimer on platelets.
- 25 July 2024
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (15) , 3917-3928
Open AccessAffimer reagents as tool molecules to modulate platelet GPVI-ligand interactions and specifically bind GPVI dimer
Glycoprotein VI (GPVI) plays a key role in collagen-induced platelet aggregation. Affimers are engineered binding protein alternatives to antibodies. We screened and characterized GPVI-binding Affimers as novel tools to probe GPVI function. Among the positive clones, M17, D22, and D18 bound GPVI with the highest affinities (dissociation constant (KD) in the nanomolar range). These Affimers inhibited GPVI-collagen-related peptide (CRP)-XL/collagen interactions, CRP-XL/collagen-induced platelet aggregation, and D22 also inhibited in vitro thrombus formation on a collagen surface under flow. D18 bound GPVI dimer but not monomer. GPVI binding was increased for D18 but not M17/D22 upon platelet activation by CRP-XL and adenosine 5′-diphosphate. D22 but not M17/D18 displaced nanobody 2 (Nb2) binding to GPVI, indicating similar epitopes for D22 with Nb2 but not for M17/D18. Mapping of binding sites revealed that D22 binds a site that overlaps with Nb2 on the D1 domain, whereas M17 targets a site on the D2 domain, overlapping in part with the glenzocimab binding site, a humanized GPVI antibody fragment antigen-binding fragment. D18 targets a new region on the D2 domain. We found that D18 is a stable noncovalent dimer and forms a stable complex with dimeric GPVI with 1:1 stoichiometry. Taken together, our data demonstrate that Affimers modulate GPVI-ligand interactions and bind different sites on GPVI D1/D2 domains. D18 is dimer-specific and could be used as a tool to detect GPVI dimerization or clustering in platelets. A dimeric epitope regulating ligand binding was identified on the GPVI D2 domain, which could be used for the development of novel bivalent antithrombotic agents selectively targeting GPVI dimer on platelets.
- Open Access
- 30 June 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1-15
RAS-inhibiting biologics identify and probe druggable pockets including an SII-α3 allosteric site
RAS mutations are the most common oncogenic drivers across human cancers, but there remains a paucity of clinically-validated pharmacological inhibitors of RAS, as druggable pockets have proven difficult to identify. Here, we identify two RAS-binding Affimer proteins, K3 and K6, that inhibit nucleotide exchange and downstream signaling pathways with distinct isoform and mutant profiles. Affimer K6 binds in the SI/SII pocket, whilst Affimer K3 is a non-covalent inhibitor of the SII region that reveals a conformer of wild-type RAS with a large, druggable SII/α3 pocket. Competitive NanoBRET between the RAS-binding Affimers and known RAS binding small-molecules demonstrates the potential to use Affimers as tools to identify pharmacophores. This work highlights the potential of using biologics with small interface surfaces to select unseen, druggable conformations in conjunction with pharmacophore identification for hard-to-drug proteins.
- 30 June 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1-15
Open AccessRAS-inhibiting biologics identify and probe druggable pockets including an SII-α3 allosteric site
RAS mutations are the most common oncogenic drivers across human cancers, but there remains a paucity of clinically-validated pharmacological inhibitors of RAS, as druggable pockets have proven difficult to identify. Here, we identify two RAS-binding Affimer proteins, K3 and K6, that inhibit nucleotide exchange and downstream signaling pathways with distinct isoform and mutant profiles. Affimer K6 binds in the SI/SII pocket, whilst Affimer K3 is a non-covalent inhibitor of the SII region that reveals a conformer of wild-type RAS with a large, druggable SII/α3 pocket. Competitive NanoBRET between the RAS-binding Affimers and known RAS binding small-molecules demonstrates the potential to use Affimers as tools to identify pharmacophores. This work highlights the potential of using biologics with small interface surfaces to select unseen, druggable conformations in conjunction with pharmacophore identification for hard-to-drug proteins.
- 1 February 2020
- Published by Elsevier in Biophysical Journal
- Vol. 118 (3) , 470a
Efficient Labeling of Estrogen Receptor α Inside Cells using Affimer, an Antibody Mimetic
- 1 February 2020
- Published by Elsevier in Biophysical Journal
- Vol. 118 (3) , 470a
Efficient Labeling of Estrogen Receptor α Inside Cells using Affimer, an Antibody Mimetic
- Open Access
- 3 October 2019
- Published by American Chemical Society (ACS) in ACS Sensors
- Vol. 4 (11) , 3014-3022
Affimer–Enzyme–Inhibitor Switch Sensor for Rapid Wash-free Assays of Multimeric Proteins
Robust technology is required to underpin rapid point-of-care and in-field diagnostics, to improve timely decision making across broad sectors. An attractive strategy combines target recognition and signal generating elements into an “active” enzyme-switch that directly transduces target-binding into a signal. However, approaches that are broadly applicable to diverse targets remain elusive. Here, an enzyme-inhibitor switch sensor was developed by insertion of non-immunoglobulin Affimer binding proteins, between TEM1-β-lactamase and its inhibitor protein, such that target binding disrupts the enzyme-inhibitor complex. Design principles for a successful switch architecture are illustrated by the rapid (min), simple (wash-free) and sensitive (pM) quantification of multimeric target analytes in biological samples (serum, plasma, leaf extracts), across three application areas. A therapeutic antibody (Herceptin), protein biomarker (human C-reactive protein, hCRP) and plant virus (cow pea mosaic virus, CPMV) were targeted, demonstrating assays for therapeutic drug monitoring, health diagnostics and plant pathogen detection, respectively. Batch-to-batch reproducibility, shelf-life stability and consistency with validated ELISA analysis confirms that the principle of an Affimer-enzyme-inhibitor switch provides a platform for point-of-care and in-field diagnostics. KEYWORDS: Protein switch, homogenous assay, wash-free diagnostics, protein engineering, Affimers, point-of-care, in-field, biosensor
- 3 October 2019
- Published by American Chemical Society (ACS) in ACS Sensors
- Vol. 4 (11) , 3014-3022
Open AccessAffimer–Enzyme–Inhibitor Switch Sensor for Rapid Wash-free Assays of Multimeric Proteins
Robust technology is required to underpin rapid point-of-care and in-field diagnostics, to improve timely decision making across broad sectors. An attractive strategy combines target recognition and signal generating elements into an “active” enzyme-switch that directly transduces target-binding into a signal. However, approaches that are broadly applicable to diverse targets remain elusive. Here, an enzyme-inhibitor switch sensor was developed by insertion of non-immunoglobulin Affimer binding proteins, between TEM1-β-lactamase and its inhibitor protein, such that target binding disrupts the enzyme-inhibitor complex. Design principles for a successful switch architecture are illustrated by the rapid (min), simple (wash-free) and sensitive (pM) quantification of multimeric target analytes in biological samples (serum, plasma, leaf extracts), across three application areas. A therapeutic antibody (Herceptin), protein biomarker (human C-reactive protein, hCRP) and plant virus (cow pea mosaic virus, CPMV) were targeted, demonstrating assays for therapeutic drug monitoring, health diagnostics and plant pathogen detection, respectively. Batch-to-batch reproducibility, shelf-life stability and consistency with validated ELISA analysis confirms that the principle of an Affimer-enzyme-inhibitor switch provides a platform for point-of-care and in-field diagnostics. KEYWORDS: Protein switch, homogenous assay, wash-free diagnostics, protein engineering, Affimers, point-of-care, in-field, biosensor
- Open Access
- 17 May 2019
- Published by Springer Nature in Scientific Reports
- Vol. 9 (1) , 1-9
Affimer reagents as tools in diagnosing plant virus diseases
Plant viruses can cause devastating losses to agriculture and are therefore a major threat to food security. The rapid identification of virally-infected crops allowing containment is essential to limit such threats, but plant viral diseases can be extremely challenging to diagnose. An ideal method for plant virus diagnosis would be a device which can be implemented easily in the field. Such devices require a binding reagent that is specific for the virus of interest. We chose to investigate the use of Affimer reagents, artificial binding proteins and a model plant virus Cowpea Mosaic virus (CPMV) empty virus like particles (eVLPs). CPMV-eVLP mimic the morphology of wild-type (WT) CPMV but lack any infectious genomic material and so do not have biocontainment issues. We have produced and purified an Affimer reagent selected for its ability to bind to CPMV-eVLP and have shown that the selected Affimer also specifically binds to WT CPMV. We have produced a 3.4 Å structure of WT CPMV bound to the Affimer using cryo-electron microscopy. Finally, we have shown that this Affimer is capable of reliably detecting the virus in crude extracts of CPMV-infected leaves and can therefore form the basis for the future development of diagnostic tests.
- 17 May 2019
- Published by Springer Nature in Scientific Reports
- Vol. 9 (1) , 1-9
Open AccessAffimer reagents as tools in diagnosing plant virus diseases
Plant viruses can cause devastating losses to agriculture and are therefore a major threat to food security. The rapid identification of virally-infected crops allowing containment is essential to limit such threats, but plant viral diseases can be extremely challenging to diagnose. An ideal method for plant virus diagnosis would be a device which can be implemented easily in the field. Such devices require a binding reagent that is specific for the virus of interest. We chose to investigate the use of Affimer reagents, artificial binding proteins and a model plant virus Cowpea Mosaic virus (CPMV) empty virus like particles (eVLPs). CPMV-eVLP mimic the morphology of wild-type (WT) CPMV but lack any infectious genomic material and so do not have biocontainment issues. We have produced and purified an Affimer reagent selected for its ability to bind to CPMV-eVLP and have shown that the selected Affimer also specifically binds to WT CPMV. We have produced a 3.4 Å structure of WT CPMV bound to the Affimer using cryo-electron microscopy. Finally, we have shown that this Affimer is capable of reliably detecting the virus in crude extracts of CPMV-infected leaves and can therefore form the basis for the future development of diagnostic tests.
- Open Access
- 2 August 2018
- Published by Oxford University Press (OUP) in The Plant Cell
- Vol. 30 (9) , 2174-2196
Predominant Golgi Residency of the Plant K/HDEL Receptor Is Essential for Its Function in Mediating ER Retention
Accumulation of soluble proteins in the endoplasmic reticulum (ER) of plants is mediated by a receptor termed ER RETENTION DEFECTIVE 2 (ERD2) or K/HDEL receptor. Using two gain-of-function assays and by complementing loss of function in Nicotiana benthamiana we discovered that compromising the lumenal N-terminus or the cytosolic C-terminus with fluorescent fusions abolishes its biological function and profoundly affects its subcellular localization. Based on the confirmed asymmetrical topology of ERD2 we engineered a new fluorescent ERD2 fusion protein that retains biological activity. Using this fusion, we show that ERD2 is exclusively detected at the Golgi apparatus, unlike non-functional C-terminal fusions which also label the ER. Moreover, ERD2 is confined to early Golgi compartments and does not show ligand-induced redistribution to the ER. We show that the cytosolic C-terminus of ERD2 plays a crucial role in its function. Two conserved Leucine residues that do not correspond to any known targeting motifs for ER-Golgi trafficking were shown to be essential for both ERD2 Golgi residency and its ability to mediate ER retention of soluble ligands. The results suggest that anterograde ER to Golgi transport of ERD2 is either extremely fast, well in excess of the bulk flow rate, or that ERD2 does not recycle in the way originally proposed.
- 2 August 2018
- Published by Oxford University Press (OUP) in The Plant Cell
- Vol. 30 (9) , 2174-2196
Open AccessPredominant Golgi Residency of the Plant K/HDEL Receptor Is Essential for Its Function in Mediating ER Retention
Accumulation of soluble proteins in the endoplasmic reticulum (ER) of plants is mediated by a receptor termed ER RETENTION DEFECTIVE 2 (ERD2) or K/HDEL receptor. Using two gain-of-function assays and by complementing loss of function in Nicotiana benthamiana we discovered that compromising the lumenal N-terminus or the cytosolic C-terminus with fluorescent fusions abolishes its biological function and profoundly affects its subcellular localization. Based on the confirmed asymmetrical topology of ERD2 we engineered a new fluorescent ERD2 fusion protein that retains biological activity. Using this fusion, we show that ERD2 is exclusively detected at the Golgi apparatus, unlike non-functional C-terminal fusions which also label the ER. Moreover, ERD2 is confined to early Golgi compartments and does not show ligand-induced redistribution to the ER. We show that the cytosolic C-terminus of ERD2 plays a crucial role in its function. Two conserved Leucine residues that do not correspond to any known targeting motifs for ER-Golgi trafficking were shown to be essential for both ERD2 Golgi residency and its ability to mediate ER retention of soluble ligands. The results suggest that anterograde ER to Golgi transport of ERD2 is either extremely fast, well in excess of the bulk flow rate, or that ERD2 does not recycle in the way originally proposed.